Validation of insulin secretion indices in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 8, Issue 6, 2009, Pages 378-381

  Hammana, I ^a,b   Potvin, S ^a,b   Tardif, A ^a   Berthiaume, Y ^b   Coderre, L ^a,b   Rabasa Lhoret, R ^a,b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Homeostasis Model Assessment (HOMA); Insulin secretion; Intravenous glucose tolerance test (IGVTT); Oral glucose tolerance test (OGTT)

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; TIME;

EID: 70449637238     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.08.007     Document Type: Article

References (27)

1. Yankaskas J.R., Marshall B.C., Sufian B., Simon R.H., and Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 125 1 Suppl (Jan 2004) 1S-39S
2. Moran A., Hardin D., Rodman D., Allen H.F., Beall R.J., Borowitz D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 45 1 (Aug 1999) 61-73
3. Costa M., Potvin S., Hammana I., Malet A., Berthiaume Y., Jeanneret A., et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros 6 6 (Apr 2 2007) 376-383
4. Lombardo F., De Luca F., Rosano M., Sferlazzas C., Lucanto C., Arrigo T., et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 149 1 (Jul 2003) 53-59
5. Lanng S., Thorsteinsson B., Lund-Andersen C., Nerup J., Schiotz P.O., and Koch C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr 83 1 (Jan 1994) 72-77
6. Costa M., Potvin S., Berthiaume Y., Gauthier L., Jeanneret A., Lavoie A., et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab 31 3 Pt 1 (Jun 2005) 221-232
7. Schaedel C., de M.I., Hjelte L., Johannesson M., Kornfalt R., Lindblad A., et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33 6 (Jun 2002) 483-491
8. Holl R.W., Heinze E., Wolf A., Rank M., and Teller W.M. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr 154 5 (May 1995) 356-361
9. Lanng S., Thorsteinsson B., Roder M.E., Orskov C., Holst J.J., Nerup J., et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh) 128 3 (Mar 1993) 207-214
10. Dobson L., Sheldon C.D., and Hattersley A.T. Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?. J R Soc Med 97 Suppl 44 (2004) 26-35
11. Scheen A.J., Paquot N., Letiexhe M.R., Castillo M.J., and Lefebvre P.J. How should insulin secretion be evaluated in practice?. Diabete Metab 21 6 (Dec 1995) 458-464
12. Magni P., Sparacino G., Bellazzi R., Toffolo G.M., and Cobelli C. Insulin minimal model indexes and secretion: proper handling of uncertainty by a Bayesian approach. Ann Biomed Eng 32 7 (Jul 2004) 1027-1037
13. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., and DeFronzo R.A. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90 1 (Jan 2005) 493-500
14. Mackie A.D., Thornton S.J., and Edenborough F.P. Cystic fibrosis-related diabetes. Diabet Med 20 6 (Jun 2003) 425-436
15. Yung B., Noormohamed F.H., Kemp M., Hooper J., Lant A.F., and Hodson M.E. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 19 3 (Mar 2002) 221-226
16. Bingley P.J., Colman P., Eisenbarth G.S., Jackson R.A., McCulloch D.K., Riley W.J., et al. Standardization of IVGTT to predict IDDM. Diabetes Care 15 10 (Oct 1992) 1313-1316
17. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 7 (Jul 1985) 412-419
18. Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Jarvinen H., Van Haeften T., et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23 3 (Mar 2000) 295-301
19. Hammana I., Coderre L., Potvin S., Costa M., Berthiaume Y., Lavoie A., et al. Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. J Cyst Fibros 8 2 (Mar 2009) 128-134
20. Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis. Cystic Fibrosis Foundation ed. Bethesda: 1994. p. 1-26.
21. Diagnosis and classification of diabetes mellitus. Diabetes Care 28 Suppl 1 (Jan 2005) S37-S42
22. Marcelli-Tourvieille S., Hubert T., Pattou F., and Vantyghem M.C. Acute insulin response (AIR): review of protocols and clinical interest in islet transplantation. Diabetes Metab 32 4 (Sep 2006) 295-303
23. Dobson L., Sheldon C.D., and Hattersley A.T. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 21 7 (Jul 2004) 691-696
24. Moran A., Doherty L., Wang X., and Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 133 1 (Jul 1998) 10-17
25. Tofe S., Moreno J.C., Maiz L., Alonso M., Escobar H., and Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 152 2 (Feb 2005) 241-247
26. Festa A., Williams K., Hanley A.J., and Haffner S.M. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57 6 (Jun 2008) 1638-1644
27. Festa A., Williams K., Hanley A.J., and Haffner S.M. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57 6 (Jun 2008) 1638-1644